Histogen Company Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function.
The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases.
Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases.
Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.
| Country | United States |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 7 |
| CEO | Susan Knudson |
Contact Details
Address: 10655 Sorrento Valley Road San Diego, Delaware 92121 United States | |
| Phone | 858 526 3100 |
| Website | histogen.com |
Stock Details
| Ticker Symbol | HSTOQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Susan Knudson | Chief Executive Officer |
| Susan Knudson | Chief Financial Officer |
| Susan Knudson | Chief Operating Officer |